Black Diamond Therapeutics (BDTX) – Analysts’ Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of Black Diamond Therapeutics (NASDAQ: BDTX) recently:

• 12/8/2025 – Black Diamond Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/3/2025 – Black Diamond Therapeutics was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.
• 12/1/2025 – Black Diamond Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Black Diamond Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Black Diamond Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/18/2025 – Black Diamond Therapeutics is now covered by analysts at Piper Sandler. They set an “overweight” rating and a $9.00 price target on the stock.
• 11/17/2025 – Black Diamond Therapeutics was upgraded by analysts at Piper Sandler to a “strong-buy” rating.
• 10/15/2025 – Black Diamond Therapeutics is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $8.00 price target on the stock.

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.